Progyny (NASDAQ:PGNY) CFO Sells $64,183.50 in Stock

Progyny, Inc. (NASDAQ:PGNY) CFO Mark Livingston sold 2,517 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $25.50, for a total transaction of $64,183.50. Following the completion of the sale, the chief financial officer directly owned 74,688 shares in the company, valued at approximately $1,904,544. This trade represents a 3.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Progyny Price Performance

Shares of Progyny stock opened at $25.86 on Monday. The company’s fifty day simple moving average is $20.58 and its two-hundred day simple moving average is $22.26. The firm has a market cap of $2.03 billion, a PE ratio of 33.58, a price-to-earnings-growth ratio of 2.28 and a beta of 1.03. Progyny, Inc. has a 12-month low of $16.10 and a 12-month high of $28.75.

Progyny (NASDAQ:PGNY) last announced its earnings results on Thursday, May 7th. The company reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.24. The firm had revenue of $328.50 million for the quarter, compared to analyst estimates of $326.47 million. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The company’s revenue for the quarter was down 26.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.17 EPS. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, sell-side analysts expect that Progyny, Inc. will post 1.07 earnings per share for the current fiscal year.

Progyny announced that its Board of Directors has authorized a share repurchase plan on Tuesday, May 26th that authorizes the company to buyback $200.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 10.3% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s management believes its stock is undervalued.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of PGNY. Royal Bank of Canada lifted its position in Progyny by 384.8% during the 1st quarter. Royal Bank of Canada now owns 13,027 shares of the company’s stock valued at $291,000 after acquiring an additional 10,340 shares during the period. Amundi lifted its position in Progyny by 103.8% during the 1st quarter. Amundi now owns 11,419 shares of the company’s stock valued at $264,000 after acquiring an additional 5,817 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Progyny by 6.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company’s stock valued at $5,630,000 after acquiring an additional 14,297 shares during the period. Invesco Ltd. lifted its position in Progyny by 37.4% during the 2nd quarter. Invesco Ltd. now owns 379,189 shares of the company’s stock valued at $8,342,000 after acquiring an additional 103,253 shares during the period. Finally, Walleye Capital LLC lifted its position in Progyny by 6.9% during the 2nd quarter. Walleye Capital LLC now owns 12,080 shares of the company’s stock valued at $266,000 after acquiring an additional 780 shares during the period. 94.93% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Zacks Research raised shares of Progyny from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. KeyCorp cut their target price on shares of Progyny from $32.00 to $28.00 and set an “overweight” rating on the stock in a research note on Monday, March 2nd. Truist Financial lifted their target price on shares of Progyny from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Citizens Jmp lifted their target price on shares of Progyny from $30.00 to $31.00 and gave the company a “market outperform” rating in a research note on Monday, May 11th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Progyny in a research note on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $29.67.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.